SG Americas Securities LLC Has $243,000 Holdings in Arvinas, Inc. (NASDAQ:ARVN)

SG Americas Securities LLC decreased its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 88.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,860 shares of the company's stock after selling 76,236 shares during the period. SG Americas Securities LLC's holdings in Arvinas were worth $243,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in shares of Arvinas during the second quarter worth approximately $42,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Arvinas during the 1st quarter worth $44,000. Amalgamated Bank increased its position in shares of Arvinas by 29.6% in the 2nd quarter. Amalgamated Bank now owns 2,223 shares of the company's stock worth $59,000 after purchasing an additional 508 shares during the last quarter. Contravisory Investment Management Inc. acquired a new stake in shares of Arvinas in the 2nd quarter valued at about $185,000. Finally, Cullinan Associates Inc. acquired a new position in Arvinas in the first quarter worth about $248,000. Institutional investors and hedge funds own 95.19% of the company's stock.

Analyst Ratings Changes

ARVN has been the topic of several research reports. Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a research note on Monday, September 9th. Barclays dropped their price target on Arvinas from $60.00 to $48.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 31st. Wedbush reaffirmed an "outperform" rating and issued a $57.00 price objective on shares of Arvinas in a report on Tuesday, July 30th. Oppenheimer lowered their target price on shares of Arvinas from $70.00 to $50.00 and set an "outperform" rating for the company in a research note on Wednesday, July 31st. Finally, HC Wainwright restated a "buy" rating and issued a $87.00 price target on shares of Arvinas in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $57.50.

Arvinas Price Performance

Shares of ARVN traded up $0.81 during trading hours on Tuesday, reaching $26.57. 481,170 shares of the company's stock traded hands, compared to its average volume of 718,734. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -4.31 and a beta of 1.97. The business's fifty day simple moving average is $25.30 and its two-hundred day simple moving average is $28.30. Arvinas, Inc. has a twelve month low of $13.57 and a twelve month high of $53.08.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($1.08) by $0.59. The company had revenue of $76.50 million for the quarter, compared to the consensus estimate of $33.27 million. During the same quarter last year, the firm posted ($1.25) earnings per share. The firm's quarterly revenue was up 40.4% compared to the same quarter last year. On average, equities research analysts expect that Arvinas, Inc. will post -3.51 EPS for the current year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.